1.68
price up icon3.70%   0.06
after-market Handel nachbörslich: 1.65 -0.03 -1.79%
loading
Schlusskurs vom Vortag:
$1.62
Offen:
$1.645
24-Stunden-Volumen:
137.67K
Relative Volume:
0.15
Marktkapitalisierung:
$181.91M
Einnahmen:
$27.08M
Nettoeinkommen (Verlust:
$-37.00M
KGV:
-3.2308
EPS:
-0.52
Netto-Cashflow:
$-18.46M
1W Leistung:
+6.33%
1M Leistung:
+20.86%
6M Leistung:
-34.12%
1J Leistung:
+20.00%
1-Tages-Spanne:
Value
$1.64
$1.68
1-Wochen-Bereich:
Value
$1.56
$1.78
52-Wochen-Spanne:
Value
$1.05
$5.17

Aclaris Therapeutics Inc Stock (ACRS) Company Profile

Name
Firmenname
Aclaris Therapeutics Inc
Name
Telefon
484-324-7933
Name
Adresse
701 LEE ROAD, WAYNE, PA
Name
Mitarbeiter
64
Name
Twitter
@aclaristx
Name
Nächster Verdiensttermin
2025-02-24
Name
Neueste SEC-Einreichungen
Name
ACRS's Discussions on Twitter

Vergleichen Sie ACRS mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
ACRS
Aclaris Therapeutics Inc
1.68 175.42M 27.08M -37.00M -18.46M -0.52
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
476.95 120.73B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
572.39 60.56B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
325.64 42.41B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
575.42 34.96B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
294.83 31.99B 3.81B -644.79M -669.77M -6.24

Aclaris Therapeutics Inc Stock (ACRS) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-07-10 Fortgesetzt Piper Sandler Overweight
2025-05-28 Eingeleitet Wedbush Outperform
2025-03-18 Fortgesetzt Cantor Fitzgerald Overweight
2024-12-23 Hochstufung H.C. Wainwright Neutral → Buy
2024-11-20 Hochstufung Cantor Fitzgerald Neutral → Overweight
2024-11-19 Hochstufung BTIG Research Neutral → Buy
2024-11-19 Hochstufung Jefferies Hold → Buy
2024-11-19 Hochstufung Leerink Partners Market Perform → Outperform
2024-11-18 Hochstufung Piper Sandler Neutral → Overweight
2024-01-22 Herabstufung H.C. Wainwright Buy → Neutral
2023-11-13 Herabstufung William Blair Outperform → Mkt Perform
2023-10-03 Eingeleitet Evercore ISI Outperform
2022-12-14 Eingeleitet Stifel Buy
2022-12-01 Eingeleitet Goldman Buy
2022-10-06 Eingeleitet BTIG Research Buy
2021-07-23 Fortgesetzt Jefferies Buy
2021-06-15 Eingeleitet Piper Sandler Overweight
2021-04-21 Eingeleitet H.C. Wainwright Buy
2019-10-22 Hochstufung SVB Leerink Mkt Perform → Outperform
2019-09-06 Herabstufung JMP Securities Mkt Outperform → Mkt Perform
2019-06-27 Herabstufung SVB Leerink Outperform → Mkt Perform
2019-05-06 Eingeleitet SVB Leerink Outperform
2018-03-28 Fortgesetzt Leerink Partners Outperform
2018-02-09 Eingeleitet Guggenheim Buy
2017-06-16 Eingeleitet Cantor Fitzgerald Overweight
2016-11-29 Eingeleitet Leerink Partners Outperform
2016-09-30 Eingeleitet JMP Securities Mkt Outperform
2016-06-10 Eingeleitet Guggenheim Buy
2015-11-02 Eingeleitet Citigroup Buy
2015-11-02 Eingeleitet Jefferies Buy
Alle ansehen

Aclaris Therapeutics Inc Aktie (ACRS) Neueste Nachrichten

pulisher
Jul 23, 2025

LENZ Therapeutics Inc. Stock Analysis and ForecastPhenomenal capital appreciation - Autocar Professional

Jul 23, 2025
pulisher
Jul 22, 2025

Aclaris Therapeutics Inc. Stock Analysis and ForecastTremendous financial leverage - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

What drives Aclaris Therapeutics Inc. stock priceDynamic growth stocks - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Is Aclaris Therapeutics Inc. a good long term investmentRapid capital growth - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

How Aclaris Therapeutics Inc. stock performs during market volatilityStrong Return Daily Alerts - Newser

Jul 22, 2025
pulisher
Jul 22, 2025

What analysts say about Aclaris Therapeutics Inc. stockPhenomenal trading returns - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 15, 2025

Why Aclaris Therapeutics Inc. stock attracts strong analyst attentionGroup Only Stock Signals - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

What makes Aclaris Therapeutics Inc. stock price move sharplyEntry Level Low Risk Picks - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

Aclaris Therapeutics Begins Phase 1 Clinical Trial for Bispecific Antibody ATI-052 Targeting Inflammatory Diseases - Insider Monkey

Jul 15, 2025
pulisher
Jul 15, 2025

13 Best Low Priced Pharma Stocks to Buy Now - Insider Monkey

Jul 15, 2025
pulisher
Jul 12, 2025

Piper Sandler Begins Coverage on Aclaris Therapeutics (NASDAQ:ACRS) - Defense World

Jul 12, 2025
pulisher
Jul 11, 2025

Aclaris Therapeutics' Recent Gains Improve Losses On Insider Purchases Worth US$1.50m - simplywall.st

Jul 11, 2025
pulisher
Jul 10, 2025

Plus Therapeutics (NASDAQ:PSTV) vs. Aclaris Therapeutics (NASDAQ:ACRS) Head-To-Head Survey - Defense World

Jul 10, 2025
pulisher
Jul 07, 2025

Aclaris Therapeutics Joins Russell 3000 and Russell 2000 Indexes - MSN

Jul 07, 2025
pulisher
Jul 07, 2025

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Receives Consensus Rating of “Buy” from Brokerages - Defense World

Jul 07, 2025
pulisher
Jun 30, 2025

Aclaris Therapeutics at HCW Conference: Strategic Moves and Future Plans By Investing.com - Investing.com Canada

Jun 30, 2025
pulisher
Jun 30, 2025

Aclaris Therapeutics joins Russell 3000 and Russell 2000 indexes - Investing.com

Jun 30, 2025
pulisher
Jun 30, 2025

Aclaris Therapeutics Added to the Russell 2000® and Russell 3000® Indexes - GlobeNewswire

Jun 30, 2025
pulisher
Jun 30, 2025

Aclaris Added to Russell Indexes: $10.6T in Benchmark Assets Now Track Biotech Stock - Stock Titan

Jun 30, 2025
pulisher
Jun 30, 2025

Aclaris Therapeutics, Inc.(NasdaqGS:ACRS) added to Russell Small Cap Completeness Index - MarketScreener

Jun 30, 2025
pulisher
Jun 30, 2025

Aclaris Therapeutics joins Russell 3000 and Russell 2000 indexes By Investing.com - Investing.com UK

Jun 30, 2025
pulisher
Jun 27, 2025

Aclaris Therapeutics to Participate in the H.C. Wainwright Inflammation & Immunology Virtual Conference - The Manila Times

Jun 27, 2025
pulisher
Jun 26, 2025

Aclaris Therapeutics to Present at H.C. Wainwright Inflammation & Immunology Virtual Conference on June 30, 2025 - Nasdaq

Jun 26, 2025
pulisher
Jun 26, 2025

Aclaris Therapeutics (NASDAQ:ACRS) Receives “Buy” Rating from HC Wainwright - Defense World

Jun 26, 2025
pulisher
Jun 25, 2025

Aclaris Therapeutics Begins Phase 1a/1b Trial for Investigational Bispecific Antibody ATI-052 - MSN

Jun 25, 2025
pulisher
Jun 24, 2025

Aclaris Therapeutics (NASDAQ:ACRS) Given Outperform Rating at Wedbush - Defense World

Jun 24, 2025
pulisher
Jun 19, 2025

Assenagon Asset Management S.A. Purchases 284,191 Shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS) - Defense World

Jun 19, 2025
pulisher
Jun 15, 2025

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Receives $9.71 Consensus Price Target from Analysts - Defense World

Jun 15, 2025
pulisher
Jun 12, 2025

Revenues Not Telling The Story For Aclaris Therapeutics, Inc. (NASDAQ:ACRS) After Shares Rise 26% - simplywall.st

Jun 12, 2025
pulisher
Jun 11, 2025

Aclaris at Goldman Sachs Conference: Strategic Focus on Immuno-inflammatory Pipeline By Investing.com - Investing.com South Africa

Jun 11, 2025
pulisher
Jun 11, 2025

Aclaris at Goldman Sachs Conference: Strategic Focus on Immuno-inflammatory Pipeline - Investing.com Australia

Jun 11, 2025
pulisher
Jun 11, 2025

Bank of America Corp DE Buys 196,708 Shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS) - Defense World

Jun 11, 2025

Finanzdaten der Aclaris Therapeutics Inc-Aktie (ACRS)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$22.87
price up icon 4.91%
$36.01
price down icon 0.25%
$103.44
price up icon 0.51%
$28.01
price up icon 5.54%
$114.60
price up icon 2.84%
biotechnology ONC
$294.83
price down icon 0.26%
Kapitalisierung:     |  Volumen (24h):